associated with MYOC mutations. 3,4 These adultonset cases feature an elevated intraocular pressure with resultant optic-nerve damage and visual loss, and they are clinically indistinguishable from cases of primary open-angle glaucoma in patients without MYOC mutations. 5 To address the mechanisms of optic-nerve damage, we broaden the discussion to include primary openangle glaucoma with elevated intraocular pressure, with or without MYOC mutations.
CLINIC A L FE AT UR ES

Epidemiology and Risk Factors
Primary open-angle glaucoma is the second leading cause of blindness in the United States and the leading cause of blindness among black Americans. 6 There is good evidence that black race, older age, elevated intraocular pressure, family history of primary open-angle glaucoma, myopia, and low diastolic perfusion pressure are risk factors for primary open-angle glaucoma. 6, 7 (Table 1). Among patients with an elevated intraocular pressure, a relatively thin central cornea is another major risk factor for the disease. 14 Evidence for other risk factors (diabetes mellitus, elevated systolic blood pressure, and migraine, among others) is less consistent. 15 
Clinical Presentation
The main clinical features of primary open-angle glaucoma are an open iridocorneal angle and cupping of the optic-nerve head (or optic disk), with corresponding loss of visual field. Elevated intraocular pressure is not part of the clinical definition because primary open-angle glaucoma can occur when intraocular pressure is normal (typically 10 to 21 mm Hg). Nevertheless, elevated intraocular pressure is an important risk factor and is also considered to be a causative factor in glau- This anterior segment of the eye shows the circulation of the aqueous humor from the ciliary body through the pupil into the anterior chamber. The aqueous humor then passes through the trabecular meshwork into Schlemm's canal and travels from there into the episcleral venous system. A smaller amount of aqueous humor leaves the eye through the face of the ciliary body, just below the trabecular meshwork. coma 16 ; currently, it is the only modifiable causative factor. Many randomized clinical trials have shown that reducing intraocular pressure slows the onset and progression of glaucoma. 17, 18 Therefore, all current treatments of primary open-angle glaucoma are aimed at reducing intraocular pressure by medical or surgical means. 19, 20 The Case Presentation recounts a typical presentation of primary open-angle glaucoma (see box for Case Presentation, and see Fig. 2 for examination results).
M yocilin
Genetic Features
Juvenile-onset primary open-angle glaucoma is rare. It has the same clinical features as the adult-onset condition, except that in the juvenileonset form the intraocular pressure is often extremely high (frequently >40 mm Hg). 21 Large pedigrees with autosomal-dominant inheritance of juvenile-onset primary open-angle glaucoma have been reported, and analyses of genetic markers in such pedigrees have mapped a glaucomarelated gene to a region of chromosome 1q designated GLC1A. 22 Subsequent linkage studies of other glaucoma pedigrees have mapped the chromosomal locations of 13 additional glaucomarelated genes (GLC1B through GLC1N). 23 The relevant gene at the GLC1A locus is MYOC (Online Mendelian Inheritance in Man number, 601652), which encodes the protein myocilin. Myocilin is produced in many tissues, including the ciliary body 24 and trabecular meshwork, 25 the two ocular tissues that regulate intraocular pres- 
Effect on the Trabecular Meshwork
Some MYOC mutations have been detected in a sufficient number of patients to allow identification of mutation-specific glaucoma phenotypes, including age at onset and maximum intraocular pressure. 35, 36 A central clinical feature of myocilin-associated glaucoma is elevated intraocular pressure, and some mutations cause higher intraocular pressure than others. Mutations associated with juvenile-onset primary open-angle glaucoma lead to the greatest elevations in intraocular pressure -often more than 40 mm Hg. Mutations associated with adult-onset primary openangle glaucoma typically cause maximum pressures of 25 to 40 mm Hg. 31, 35 In patients with MYOC mutations, high intraocular pressure appears to be important not only for the onset of glaucoma but also for progression of the disease. These effects suggest that MYOC mutations encode a protein that causes microscopic abnormalities in the structures of an otherwise normal-appearing iridocorneal angle, especially the trabecular meshwork.
The function of myocilin is unknown. Analysis of its amino acid sequence has revealed functional domains, including a leucine zipper domain for protein-protein interactions and two domains that can influence protein localization. The N-terminal of myocilin has a signal sequence that targets proteins for secretion, whereas the last three amino acids at the C-terminal of myoCase Presentation: Primary Open-Angle Glaucoma History A 71-year-old white woman was referred to an ophthalmologist because of declining vision. A diagnosis of glaucoma had been made 10 years earlier, with intraocular pressures (mm Hg) in the mid-20s. She underwent laser trabeculoplasty of the left eye before the referral and was treated with topical antiglaucoma medications (timolol and latanoprost) at the time of the referral. She had no other medical problems. Her 49-year-old nephew had glaucoma.
Examination
On ocular examination, her visual acuity was 20/25 in each eye. She also had mild cataracts in both eyes. Her iridocorneal angles were open, and the intraocular pressure was slightly elevated, at 22 mm Hg, in both eyes, on the two medications. Fundus examination revealed cupped optic disks, with superior notching of the cup in the right eye ( Fig. 2A and 2B ) and generalized thinning of the neuroretinal rim in the left eye ( Fig. 2D and 2E ). Automated perimetry testing (Humphrey Field Analyzer, Carl Zeiss Meditec) revealed corresponding loss of visual field in both eyes ( Fig. 2C and 2F).
Diagnosis and Management
The diagnosis of primary open-angle glaucoma was confirmed. Given the extent of the opticnerve damage and vision loss, further lowering of the intraocular pressure was recommended.
Follow-up
Over the course of the next 7 years, the patient underwent additional medical and surgical treatment for glaucoma (laser trabeculoplasty in the right eye and trabeculectomy in the left eye). At the last follow-up visit, her intraocular pressure was 18 mm Hg in the right eye and 12 mm Hg in the left eye, with stable visual fields. With her consent, she was screened for mutations in the gene encoding myocilin (MYOC) as part of a research study. She was found to have an MYOC Gln368Stop mutation. cilin encode a sequence that directs intracellular proteins to peroxisomes. 37 Wild-type myocilin protein is secreted, which suggests that the peroxisomal targeting sequence is not functional under normal circumstances. The vast majority of glaucoma-associated MYOC mutations lie within a large segment of myocilin protein that is homologous to olfactomedin proteins, a family of secreted proteins with unknown function. 31 Myocilin has been detected in the trabecular meshwork, which is the principal structure of the eye that regulates intraocular pressure. 25, 38, 39 It has also been found secreted in the growth medium of primary cultures of human trabecularmeshwork cells and in human and mouse aqueous humor, indicating that myocilin is secreted from trabecular-meshwork cells in vitro and that in vivo it is secreted from ocular tissues that may include the trabecular meshwork or ciliary body. 38, [40] [41] [42] Recombinant myocilin protein, myocilin in aqueous humor, and myocilin in medium from cultured cells can self-associate and form multimers. 25, 38, 43 Decreased Secretion MYOC mutations do not appear to cause glaucoma as a result of haploinsufficiency or overexpression. Deficiencies in myocilin production resulting from a hemizygous deletion 44 or a presumed homozygous null mutation (i.e., Arg46Stop) 45 do not cause glaucoma. Similarly, glaucoma does not develop in mice with overexpression of myocilin or with deficient myocilin production. 46, 47 These results suggest that disease-causing mutations alter the myocilin protein in such a way that it disrupts the regulation of intraocular pressure. Indeed, MYOC mutations associated with glaucoma do alter the properties of the protein -disease-associated mutations reduce the solubility of myocilin in a detergent, whereas benign sequence Panel A shows a photograph of the right optic disk, and the accompanying illustration in Panel B shows the superior notching (arrow) of the cup (C), which represents a focal loss of the neuroretinal rim (R). In addition, the lamina cribrosa (LC), a dense band of collagen and glial tissue within the cup that has multiple openings for nerve fiber bundles, has become visible because of the loss of overlying neuronal tissue. In Panel C, the results of Humphrey visual-field testing show the loss of visual field in total deviation plots. The upper plot shows the numerical deviation of individual test points, in decibels, from the values of a normative database adjusted for age, and the lower plot shows the probability of test points' being normal (the darker the square, the lower the probability). There is a substantial loss of visualfield sensitivity throughout, which is slightly worse inferiorly. polymorphisms have no such effect. 48 Glaucomaassociated mutations also reduce the secretion of myocilin in vitro and in vivo. Secretion of myocilin is dramatically reduced in trabecular-meshwork cells cultured from patients with glaucoma-associated MYOC mutations. 40 Similarly, MYOC mutations greatly reduce the quantity of myocilin that is secreted into the aqueous humor, 40 supporting the idea that failure to secrete myocilin is a central feature in the pathogenesis of myocilin-associated glaucoma (Fig. 3) . MYOC mutations may prevent the secretion of myocilin by exposing a cryptic domain that directs proteins to peroxisomes, and there is evidence that mutant myocilin may be retained within the intracellular space by means of an abnormal association with proteins of the peroxisome-targeting system. 49 Other studies in mice have shown that mutations in the murine myocilin gene (Myoc) can inhibit secretion of myocilin and cause some signs of glaucoma without a cryptic targeting domain. 50 Regardless of the mechanism of retention, decreased secretion and increased accumulation of intracellular myocilin appear to be initial steps in the pathogenesis of myocilin-associated glaucoma. In Panel A, wild-type myocilin protein (green symbols) is produced in the endothelial cells of the trabecular meshwork and passes through the secretory pathway to reach the extracellular space. In the first step in this process, messenger RNA (mRNA) is transcribed from the gene encoding myocilin (MYOC) and is delivered to ribosomes at the endoplasmic reticulum, where the mRNA directs the synthesis of myocilin. Next, transport vesicles convey myocilin to the cell membrane through the Golgi apparatus. These vesicles fuse with the cell membrane and release myocilin into the extracellular space and aqueous humor. Along the secretory pathway, molecules of myocilin may associate with each other and form multimers (dimers and tetramers are depicted). In Panel B, heterozygous mutations of the MYOC gene are associated with an autosomal dominant form of glaucoma. The wild-type copy of MYOC encodes normal myocilin protein (green symbols), and the mutant MYOC copy encodes mutant myocilin protein (red symbols). Myocilin protein forms multimers that may be composed of both wild-type and mutant subunits. Secretion of mutant myocilin protein and multimers containing mutant subunits is greatly reduced, leading to the retention of the mutant protein in the endoplasmic reticulum and intracellular vesicles of trabecular-meshwork cells. Injury or death of trabecular-meshwork cells has been implicated in the pathogenesis of openangle glaucoma. 51 Endothelial cells of the tra becular meshwork maintain its structure and facilitate the outflow of aqueous humor from the eye by remodeling this porous tissue and preventing debris from occluding the outflow pathway. A reduction in cellularity and alterations in the architecture of the trabecular meshwork have been observed in glaucoma, 52 and these changes may increase resistance to aqueous outflow, thereby elevating intraocular pressure and eventually damaging the optic nerve. 51, 53 Mutant myocilin that accumulates in the intracellular space may be toxic to trabecular-meshwork cells, initiating a cascade of events that begins with loss of function in these cells, which damages the outflow pathway and results in elevated intraocular pressure. The finding that aqueous humor outflow is reduced in patients with MYOC mutations supports this hypothesis. 54 The development of animal models of myocilin-associated glaucoma 50,55,56 provides new tools for exploring the effects of mutations in the myocilin gene on the structure and function of the outflow pathway at the tissue, cellular, and subcellular levels. In particular, these animal models will facilitate studies of the effects of MYOC mutations on the health and numbers of trabecular-meshwork cells and the
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AUTHOR PLEASE NOTE: organization of the extracellular structure of the trabecular meshwork.
Da m age t o the Op tic-Nerv e He a d
It is generally believed that elevated intraocular pressure -regardless of its cause -triggers a common set of cellular events. The optic-nerve head consists of axons projected from retinal ganglion cells, which exit the eye through the lamina cribrosa, a collagenous structure with sievelike openings (Fig. 4A) . The lamina cribrosa separates unmyelinated prelaminar retinal ganglion-cell axons from myelinated postlaminar retinal ganglion-cell axons. The optic-nerve head also contains retinal vasculature (the central retinal artery and vein) and such glial elements as microglia, astrocytes, and oligodendrocytes (the oligodendrocytes are present only in the postlaminar region and are important in postlaminar axon myelination). 57, 58 We outline several key mechanisms of optic-nerve damage that are caused by elevated intraocular pressure, although damage that is independent of elevated intraocular pressure may also occur in primary openangle glaucoma. We limit the discussion to recent literature; more comprehensive reviews of the subject can be found elsewhere. [59] [60] [61] 
Cellular Stress
Elevated intraocular pressure has direct effects on retinal ganglion cells. Axonal transport decreases in the presence of elevated intraocular pressure. 62 The reduced retrograde axoplasmic flow can stress retinal ganglion cells and cause their death from deprivation of neurotrophic factors such as brain-derived neurotrophic factor. [62] [63] [64] If blood perfusion at the optic-nerve head is persistently reduced, 65-67 tissue hypoxia can induce the formation and accumulation of reactive oxygen species in the retina, and this accumulation causes cellular stress and malfunction. 68 In glaucoma, proteins and lipids with oxidative modifications accumulate in the retina and optic-nerve head, and antioxidant treatments have some benefit in animal models. [69] [70] [71] [72] [73] The use of microarray technology in animal models has shown that changes in the gene-expression profile of the retina occur rapidly in response to elevated intraocular pressure. 74,75 These changes include decreased expression of many genes specific to retinal ganglion cells 74,76-79 and increased expression of markers of hypoxia and glial activation. 65, 80, 81 Glial cells in the optic-nerve head (microglia and astrocytes) become activated in response to the elevated intraocular pressure in glaucoma 82-85 (Fig. 4B) . Activated astrocytes synthesize molecules that lead to degradation and remodeling of the extracellular matrix, and these changes can have biomechanical effects on the optic-nerve head that in turn increase stress on retinal ganglion-cell axons. 86, 87 In a mouse model of glaucoma, activated glial cells released tumor necrosis factor α (TNF-α), a proinflammatory cytokine. 88 Deletion of the genes encoding TNF-α or its receptor increased the survival of retinal ganglion cells in this model. 88, 89 Intravitreal injection of TNF-α causes loss of retinal ganglion-cell axons and subsequently loss of entire cells, even in the absence of elevated intraocular pressure. These results suggest that TNF-α can be a mediator of damage of retinal ganglion-cell axons when intraocular pressure is elevated. The presence of TNF-α in human glaucomatous retina 90 and optic-nerve head 91 has been detected by immunohistochemical analysis. Collectively, this evidence suggests that glial activation and TNF-α are important mediators of damage to retinal ganglion-cell axons. 88, 90, 91 
Structural Changes
Cupping of the optic-nerve head results from the loss of prelaminar tissue and posterior deformation of the lamina cribrosa. Three-dimensional histomorphometric studies of primates with experimentally induced glaucoma raised the possibility that one of the early changes in the structure of the optic-nerve head in glaucoma is the thickening -rather than thinning -of prelaminar tissue. 87, 92 This change is accompanied by microglial proliferation. 93 Subsequently, the lamina cribrosa bows posteriorly (Fig. 4C) . These changes in the lamina cribrosa, combined with the eventual loss of prelaminar tissue, make the cup larger and deeper. The biomechanical consequences of these changes are believed to strain retinal ganglion-cell axons, which further compromises their function. 87 These morphologic findings are accompanied by changes in the composition of the extracellular matrix of the optic-nerve head, including increased synthesis of collagen IV, proteoglycans, adhesion molecules, and matrix metalloproteinases and a loss of gap-junction communication that accompanies astrocyte acti vation. 83, 86, 94, 95 
Damage to Retinal Ganglion-Cell Axons
Clinical observations have indicated that the opticnerve head, and more specifically the lamina cribrosa, is the initial site of glaucomatous damage. 96 In animal models, and presumably also in human glaucoma, damage to retinal ganglion-cell axons precedes the death of the cells 97,98 ( Fig. 4B  and 4C ). In the DBA2/J mouse strain, elevated intraocular pressure develops spontaneously at 7 to 9 months of age, and soon thereafter, axonal shrinkage and decreased retrograde transport occur, even though the soma of the retinal ganglion cells appears normal. 99 In these mice, the retinal ganglion-cell axons proximal to the point of myelination survive, suggesting that damage to the axons occurs in an area that corresponds to the lamina cribrosa in primates. 77,97 However, retinal ganglion cells survive for only about 1 to 2 months after axonal degeneration. 77,97 Thus, the degradation of the retinal ganglion-cell axon and soma may involve separate mechanisms. 100 In DBA/2 mice, damage to retinal ganglion-cell axons occurs despite the absence of the collagenous lamina cribrosa plates typically found in primates. 101 This finding suggests that a cell-mediated mechanism underlies the damage, perhaps involving excessive synthesis of extracellular matrix material 83, 86, 94, 95 or elevation of intra-axonal calcium levels resulting from overexpression of ephrin-B2 (a receptor tyrosine kinase in glioma cells). 102,103
Loss of Retinal Ganglion Cells
Axonal damage and chronic stress result in the death of retinal ganglion cells. Most, if not all, of the loss of retinal ganglion cells in the glaucomatous retina occurs through apoptosis. 104, 105 Inhibition of apoptosis by deletion of the Bax gene in a mouse model of glaucoma almost completely rescues the retinal ganglion-cell soma, but axons are not preserved. 100 By means of noninvasive direct imaging of apoptotic cell death, 106 it has been possible to observe progressive loss of retinal ganglion-cell axons and cell bodies in a rat model of glaucoma. Coupled with thinning and further posterior bowing of the lamina cribrosa, apoptotic loss of the retinal ganglion cells results in a large, deep cup, as seen clinically in advanced glaucoma (Fig. 4D) .
Retinal ganglion-cell death is not accompanied by prominent infiltration of mononuclear cells, although there is indirect evidence of inflammatory processes, as indicated by the presence of autoantibodies against retinal antigens in patients with glaucoma. 81 Instead, glial cells phagocytose cellular debris and initiate a scar response after retinal ganglion-cell death. Inflammation-like glial activity is frequently observed in degenerative disorders of the central nervous system and is referred to as neuroinflammation, a process distinct from the adaptive immune response and more akin to a reaction of the innate immune system. 107 In glaucoma, glial expression of major-histocompatibility-complex (MHC) class II molecules 108 and synthesis of components of the complement cascade 109,110 occur as retinal ganglion-cell death continues, and these processes may further contribute to the degeneration of retinal ganglion cells.
Conclusions
In glaucoma, a major cause of blindness, the ganglion-cell axons that make up the optic nerve are damaged by a variety of factors, only some of which are understood. The most important risk factor for glaucoma is elevated intraocular pressure. Because the optic-nerve damage in glaucoma is not yet amenable to direct treatment, we provide treatment for the only known risk factor that can be modified, elevated intraocular pressure. As more is understood about the molecular biology of the trabecular meshwork and optic nerve in health and disease, our ability to treat glaucoma will likely improve. Dr. Fingert reports receiving grant support from Alcon Research and holding several unlicensed patents related to gene discovery in glaucoma, and Dr. Alward reports holding an unlicensed patent for the diagnosis of MYOC mutations. No other potential conflict of interest relevant to this article was reported.
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